Patents Represented by Attorney, Agent or Law Firm Megan E. Williams
-
Patent number: 6824779Abstract: The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The methods comprise contacting the immune cell with an agent which inhibits B7-2 binding with its natural ligand, to thereby inhibit the interaction. Examples of such agents are provided, and include a soluble form of B7-2, an antibody that recognized B7-2. The method may also include contacting the immune cell with an agent that blocks the interaction of B7-1 with its natural ligand. Further, the method may include contacting the immune cell with an immunomodulating agent, for example, an antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug. Both in vivo and in vitro applications of the method are disclosed.Type: GrantFiled: October 22, 1999Date of Patent: November 30, 2004Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLCInventors: Gordon J. Freeman, Lee M. Nadler, Gary S. Gray
-
Patent number: 6821779Abstract: The instant methods pertain to improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4° C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvest cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.Type: GrantFiled: August 17, 2001Date of Patent: November 23, 2004Assignees: University Hospital Groningen, Inc., Diacrin, Inc.Inventors: Jan Koopmans, Douglas B. Jacoby, Jonathan Dinsmore
-
Patent number: 6808710Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.Type: GrantFiled: August 23, 2000Date of Patent: October 26, 2004Assignees: Genetics Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Clive Wood, Gordon J. Freeman
-
Patent number: 6750334Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: GrantFiled: February 2, 1996Date of Patent: June 15, 2004Assignee: Repligen CorporationInventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
-
Patent number: 6713245Abstract: The instant methods pertain to an improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4° C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvested cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.Type: GrantFiled: July 6, 1998Date of Patent: March 30, 2004Assignees: Diacrin, Inc., University Hospital GroningenInventors: Jan Koopmans, Douglas B. Jacoby, Jonathan Dinsmore
-
Patent number: 6653444Abstract: Isolated nucleic acid molecules encoding a B cell activation antigen, B7, are provided. In one embodiment, the nucleic acid molecules are DNA sequences. The DNA sequences of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also provided are host cells transformed to produce proteins or peptides encoded by the DNA molecules of the present invention and purified proteins and peptides which comprise at least a portion of the B cell activation antigen. The proteins and peptides comprise at least a portion of the mature form of the B7 activation antigen and preferably comprise a soluble form of the B7 protein.Type: GrantFiled: May 30, 1995Date of Patent: November 25, 2003Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Gordon J. Freeman, Arnold S. Freedman, Lee M. Nadler
-
Patent number: 6645766Abstract: The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5′ and 3′ ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.Type: GrantFiled: January 7, 2002Date of Patent: November 11, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Pei Wen Yu, James Lorens
-
Patent number: 6632608Abstract: The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell subset activity, using XBP-1-containing indicator compositions or XBP-1-deficient cells, are provided. Methods of modulating hepatocyte growth, plasma cell differentiation and/or T cell subset activity (e.g., Th2 cytokine production) using agents that modulate the activity of XBP-1 are also provided. Methods for diagnosing disorders associated with aberrant hepatocyte growth, plasma cell differentiation and/or T cell subset activity, by assessing a change in XBP-1 expression, are also provided. XBP-1 deficient cells, animals and embryos, as well as kits for the methods of the invention, are also provided by the invention.Type: GrantFiled: December 29, 2000Date of Patent: October 14, 2003Assignee: President and Fellows of Harvard CollegeInventors: Laurie H. Glimcher, Andreas M. Reimold
-
Patent number: 6623980Abstract: The present invention is directed to novel exocytotic polypeptides, such as Exo1 and Exo2 polypeptides and related molecules, which have an inhibitory effect on exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which mediate exocytotic polypeptide bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: February 23, 1999Date of Patent: September 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Joseph Fisher, James Lorens, David Anderson, Ying Luo, Chao Bai (Betty) Huang, Mary Shen
-
Patent number: 6613327Abstract: Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated costimulatory signal in a T cell such that spontaneous abortion in the subject is inhibited. The subject methods are also based on the levels of adhesion molecules, inflammatory cytokines, and immune cell surface molecules which are altered in spontaneous abortion.Type: GrantFiled: July 28, 2000Date of Patent: September 2, 2003Assignee: Genetics Institute, Inc.Inventors: Vincent Ling, Gary S. Gray, James C. Keith, Srinivas Maganti
-
Patent number: 6610288Abstract: Isolated porcine hepatocytes, isolated populations of such hepatocytes and methods for using the hepatocytes to treat subjects with disorders characterized by insufficient liver function are described. The porcine hepatocytes can be either hepatocytes isolated from adult, immature, or embryonic swine. The porcine hepatocytes can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine hepatocytes of the invention can be used to treat disorders characterized by insufficient liver function by administering the hepatocytes to a subject having such a disorder.Type: GrantFiled: May 24, 1996Date of Patent: August 26, 2003Assignees: Diacrin, Inc., Trustees of Boston UniversityInventors: Albert Edge, J. Ryan Gunsalus, Nezam H. Afdhal
-
Patent number: 6576754Abstract: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 9, 1995Date of Patent: June 10, 2003Assignee: Dana-Farber Cancer InstituteInventors: Kathryn T. Hall, Gordon J. Freeman, Joachim L. Schultze, Vassiliki A. Boussiotis, Lee M. Nadler
-
Patent number: 6573365Abstract: Isolated nucleic acid molecules encoding a novel protein, NIP45, that interacts with members of the Nuclear Factor of Activated T cell (NF-AT) family of proteins, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed, including methods for detecting NIP45 protein or mRNA in a biological sample, methods of modulating NIP45 activity in a cell, and methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein.Type: GrantFiled: July 17, 2000Date of Patent: June 3, 2003Assignee: President and Fellows of Harvard CollegeInventors: Laurie H. Glimcher, Martin R. Hodge
-
Patent number: 6521749Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 21, 2000Date of Patent: February 18, 2003Assignee: Genetics Institute, Inc.Inventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Patent number: 6517833Abstract: Compositions comprising porcine retinal cells and methods for using the compositions to treat retinal disorders are described. The porcine retinal cells are preferably fetal neural retina cells or retinal pigment epithelial cells. The porcine retinal cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine retinal cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine retinal cells are obtained from a pig predetermined to be free from organisms which originate in pig and which are capable of transmitting infection or disease to the recipient subject.Type: GrantFiled: June 12, 2001Date of Patent: February 11, 2003Assignee: Diacrin, Inc.Inventor: Albert Edge
-
Patent number: 6485973Abstract: Disclosed are synthetic oligonucleotides complementary to a transcript of the marORAB operon which inhibit expression of a gene in the operon. Also disclosed are methods of reducing bacterial resistance to antibiotics, and pharmaceutical formulations containing marORAB-specific oligonucleotides of the invention.Type: GrantFiled: June 16, 2000Date of Patent: November 26, 2002Assignees: Hybridon, Inc., Trustees of Tufts CollegeInventors: Stuart B. Levy, Eric Von Hofe
-
Patent number: 6448006Abstract: The invention relates to methods and compositions for manipulating bacterial resistance to non-antibiotic antibacterial compositions, disinfectants and organic solvents. The invention provides methods for rendering bacterial cells susceptible to non-antibiotic antibacterial compositions. Also provided are methods to reduce the selection of bacterial mutants having an multiple antibiotic resistance phenotype by non-antibiotic antibacterial compositions. The invention also provides methods for testing the ability of non-antibiotic antibacterial compositions to select for or induce a multiple antibiotic resistance phenotype in bacteria. Also provided are methods for increasing or decreasing bacterial tolerance to organic solvents by increasing or decreasing the activity of bacterial organic solvent efflux pumps. Compositions useful in the foregoing methods are also provided.Type: GrantFiled: February 29, 2000Date of Patent: September 10, 2002Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 6444205Abstract: Methods for using neural cells to treat chronic pain and/or spasticity are described. The neural cells can be derived from any mammal, and are preferably human or porcine in origin. The neural cells preferably are serotonergic cells or are gamma-aminobutryic acid (GABA)—producing cells. Neural cells can be obtained from adult, juvenile, embryonic or fetal donors. Neural cells can be modified to be suitable for transplantation into a subject. For example, the neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject or can be genetically modified to produce a factor.Type: GrantFiled: September 30, 1998Date of Patent: September 3, 2002Assignee: Diacrin, Inc.Inventors: Jonathan Dinsmore, Julie Siegan
-
Patent number: 6444792Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: GrantFiled: January 8, 1999Date of Patent: September 3, 2002Assignee: Repligen CorporationInventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert, Sandra Silver
-
Patent number: 6391545Abstract: An isolated and cloned region of a bacterial chromosome containing a multiple antibiotic resistance operon is disclosed. A description of the structure and function of the operon is provided as are assorted recombinant DNA constructs involving the operon or fragments thereof. The diagnostic, therapeutic and experimental uses of these constructs are also disclosed. Methods of evaluating the antibiotic effectiveness of compositions are disclosed and methods of treatment employing effective compositions are provided.Type: GrantFiled: July 17, 1998Date of Patent: May 21, 2002Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy